GET DAILY SIGNALSAutolus Therapeutics (AUTL) Retraces -17% in 30 Days After August Gains
Key Takeaways
- AUTL declined roughly 17% over the trailing 30 days, falling from about $1.86 to near $1.55, unwinding a large portion of its August rally.
- The pullback reflected profit-taking and mean reversion after a sharp, earnings-driven surge rather than any single negative company event.
- Over the trailing quarter, shares are still modestly higher, having climbed to a mid-August peak near $2.54 before fading to current levels.
- Fundamentals improved in Q2 2026, with AUCATZYL revenue up 119% year over year and gross margin reaching 55%, though the company remains unprofitable.
- Near-term catalysts include third-quarter 2026 results on November 10 and longer-term CARLYSLE lupus data at ACR Convergence 2026.
- For deeper context on valuation and expectations, explore Autolus Therapeutics' Price Targets, Earnings, and Forecast on dedicated pages.
- Discover which automated strategies are active on this ticker by exploring Trending AI Robots.
Autolus Therapeutics (AUTL) Company Overview and Market Position
Autolus Therapeutics plc is a UK-headquartered, commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for cancer and autoimmune diseases. Its lead asset, AUCATZYL (obe-cel), is a CD19-directed CAR T cell therapy approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The pipeline also covers lupus, multiple sclerosis, light-chain amyloidosis, and pediatric indications. I have been following AUTL for its commercial launch progress, expanding gross margins, and autoimmune growth plans backed by the Nucleus facility in the UK plus more than 80 U.S. treatment centers.
Autolus Therapeutics (AUTL) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, AUTL moved from a closing price near $1.86 down to roughly $1.55, a decline of approximately 17%. The drop unfolded gradually, with the sharper portion appearing around mid-October. Looking back over the trailing quarter tells a different story. Shares started near $1.45 in late July, climbed to an intraday high above $2.50 in mid-August after strong second-quarter results and a financing update, then gave back most of those gains. On balance, the stock remains modestly higher for the quarter even after the recent pullback.
What Drove AUTL Stock Price in the Last 30 Days
The 30-day decline largely represented profit-taking after the August move rather than any single negative catalyst. Following second-quarter results on August 11 that beat expectations and led to raised full-year revenue guidance, shares reached a multi-month peak before momentum eased. In the weeks since, investors appear to have taken profits while refocusing on ongoing concerns such as net losses, cash burn, and reliance on a single commercial product in AUCATZYL. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Institutional ownership has softened somewhat, hedge fund holdings declined, and short interest sits near 5% of float. Management had noted potential seasonal variability in quarterly revenue, which likely added to a more measured tone ahead of the next report.
What Drove AUTL Stock Performance Over the Last Quarter
The broader quarterly picture centered on a sharp re-rating followed by partial reversal. On August 3, the company released preliminary second-quarter net product revenue figures and announced a five-year, interest-only credit facility of up to $250 million with Perceptive Advisors, which triggered heavy trading. One week later, full second-quarter results showed AUCATZYL revenue of $45.7 million, up 119% year over year, with gross margin expanding to 55% from 6% in the prior quarter. Full-year 2026 revenue guidance was raised to $140 million to $150 million. Those updates lifted shares from roughly $1.45 to a peak near $2.54. Since then, the lack of immediate new catalysts, combined with ongoing profitability questions and dilution concerns, has allowed the stock to settle back toward the lower half of its 52-week range.
AUTL Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the key near-term event is Autolus' third-quarter 2026 earnings report scheduled for November 10, which should show whether AUCATZYL revenue momentum continued and whether gross margins are tracking toward the 65% to 70% target. Later in the year, longer-term follow-up data from the CARLYSLE trial in systemic lupus erythematosus at ACR Convergence 2026 could influence views on the autoimmune pipeline. Early data from the AUTO8 program in light-chain amyloidosis and initial BOBCAT results in progressive multiple sclerosis are also expected in coming quarters. Cash runway, financing needs, and competitive dynamics in the CAR-T space remain important to monitor, along with efforts to diversify revenue beyond the single marketed product.
Using Tickeron AI Tools for Additional Perspective
In my own research process, I have found value in reviewing automated strategies alongside traditional analysis. Tickeron’s Trending AI Robots section highlights top-performing bots across different timeframes and approaches, which can help identify which algorithmic methods are currently showing results on a given ticker. This offers a useful complement when evaluating names like AUTL that have experienced sharp moves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AUTL in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 13, 2026
AUTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 38 cases where AUTL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AUTL's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUTL advanced for three days, in 223 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AUTL as a result. In 57 of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
AUTL moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AUTL crossed bearishly below the 50-day moving average on September 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for AUTL entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. AUTL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.513) is normal, around the industry mean (3.037). P/E Ratio (-1.462) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of cancer treatments
Industry Biotechnology
Advertisement